In times of crisis it is often the case that innovation strives. This time, the biotech and pharma industry has stepped up, and it very much looks like it will deliver the goods.
Earlier this year, many thought it was unthinkable to develop a vaccine from scratch within less than 18 months. Through the work we do as investors we had been looking at messenger RNA (mRNA) for some years, and to us, if someone can develop a vaccine, it will be the companies that have worked for some time on this new drug/vaccine modality.
Indeed, this week BioNTech and its partner, Pfizer announced that BNT162b2 (an mRNA for the SARS-CoV-2 spike protein) achieved success in the first interim analysis from their phase 3 study. This is a remarkable achievement.[1]
In August last year, I met with the Chief Medical Officer of BioNTech at the company’s headquarters in Mainz, Germany and discussed the immune system, cancer and the upcoming initial public offering (IPO). We had been fortunate to invest pre-IPO and we were puzzled how little interest there was in this cancer mRNA company. Fast forward to today and the world could not be more different.
Here is a biotech that has worked 24/7 since the beginning of the year, prioritised vaccine development and made sure it has a strong partner to accelerate development, manufacturing and distribution. This is biotech and pharma at its best.
It comes down to science, people and funding - the key aspects we pay close attention to in our everyday search for new technologies and innovations.
For more information:
A more detailed explanation of mRNA can be found here: https://www.platinumworldportfolios.ie/Insights/The-Journal/COVID-19-Demystifying-this-Frightening-Disease
A short video which features Bianca talking about a selection of biotech investments, including BioNTech, can be found here: https://www.platinumworldportfolios.ie/Insights/The-Journal/Biotechs-Changing-the-Future-of-Health-Care
[1] https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against
DISCLAIMER: This information has been prepared by Platinum Investment Management Limited ABN 25 063 565 006 AFSL 221935, trading as Platinum Asset Management ("Platinum") the investment manager of Platinum World Portfolios plc ("PWP"). Platinum World Portfolios plc ("Company") is an investment company with variable capital incorporated with limited liability in Ireland with registered number 546481 and established as an umbrella fund with segregated liability between sub-funds pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 (as amended) ("UCITS Regulations").
This information is accurate at the time of publication. This information is general information only and has not been prepared taking into account any particular investor’s investment objectives, financial situation or needs, and should not be used as the basis for making an investment decision. You should obtain professional advice prior to making any investment decision. The market commentary reflects Platinum’s views and beliefs at the time of preparation, which are subject to change without notice. No representations or warranties are made by Platinum as to their accuracy or reliability. To the extent permitted by law, no liability is accepted by Platinum or any other company in the Platinum Group, including any of their directors, officers or employees, for any loss or damage arising as a result of any reliance on this information.
Investing is not without risk. Neither Platinum, any company of the Platinum Group, nor any of the respective directors and officers of the aforementioned, guarantee the performance of any investment product, strategy or fund referenced herein, the repayment of capital, or the payment of income. Past performance is not a reliable indicator of future performance.
Platinum UK Asset Management Limited ("Platinum UK") has been appointed as a sub-distributor of PWP. Platinum UK is a tied agent of Mirabella Advisers LLP, which is authorised and regulated by the Financial Conduct Authority - number 606792. The content has been approved by Mirabella Advisers LLP. In the United Kingdom, this information is aimed solely at professional clients within the meaning of Article 4.1(10) of the Markets in Financial Services Directive 2014/65/EU (MiFID II) ("Relevant Persons"). No UK person other than a Relevant Person should act or rely on this information.